Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Xerava

(Eravacycline)

Phase 3Small molecule

TTetraphase Pharmaceuticals, Inc

Xerava is one of 68 small molecule programs targeting Neutropenia. It is currently in Phase 3.

2

Indications

12

Total Trials

3

Active Trials

67

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

4

Patents

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Urinary Tract InfectionActive, not recruiting

NeutropeniaPhase 2

Active, not recruiting

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

163 competitors in Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Medrol

Merrem

BB. Braun Medical Inc.

Rocephin

CConrado Roberto Hoffmann Filho

Decadron

AAspen Global Incorporated

Piperacillin/tazobactam

Prulifloxacin

Amoxicillin/clavulanate Potassium

Johnson & Johnson

Blujepa

GGlaxo Dba Glaxosmithkline

Amoxicillin/clavulanate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Study completion

NCT06440304

Q1 2028

Phase 2Recruiting

Neutropenia

NCT05537896

Q1 2029

Phase 2Recruiting

Complicated Intra-Abdominal Infections

NCT06794541

Clinical

Trials by Indication[1]

Complicated Intra-abdominal Infections3 trials

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting·TTetraphase Pharmaceuticals, Inc·Phase 2·NCT06794541·35 enrolled

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT01844856·541 enrolled

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT02784704·500 enrolled

Urinary Tract Infection2 trials

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT01978938·908 enrolled

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT03032510·1,205 enrolled

Combination Therapy2 trials

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Unknown status·SSichuan Provincial People's Hospital··NCT06223100·100 enrolled

Eravacycline Combination Therapy for MRAB

Unknown status·FFujian Medical University Union Hospital··NCT06282835·20 enrolled

Hepatic Function1 trial

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT02135302·24 enrolled

End-Stage Renal Disease1 trial

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT02135276·12 enrolled

2 more indications

Neutropenia1 trial

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting·WWest Virginia University·Phase 2·NCT05537896·55 enrolled

Unspecified2 trials

A Safety and PK Study of IV Eravacycline

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT03696550·19 enrolled

Therapeutic Options for CRAB

Recruiting·—·Phase 4·NCT06440304·108 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 27, 2018

XERAVA

NDA NDA211109

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Eravacycline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eravacycline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eravacycline. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA211109). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Xerava. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Tetraphase Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTetraphase Pharmaceuticals, Inc

Patent Landscape[5]

Patent Cliff

Aug 7, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8796245Aug 7, 2029

8906887Dec 28, 2030

11578044Oct 19, 2037

10961190Oct 19, 2037

Related News